
Annual report 2024
added 02-28-2026
argenx SE EBITDA 2011-2026 | ARGX
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA argenx SE
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -349 M | -478 M | -199 M | -81.8 M | - | -21.1 M | -15.4 M | -10.6 M | -6.11 M | -9.85 M | -3.42 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.42 M | -478 M | -117 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Apellis Pharmaceuticals
APLS
|
57 M | $ 20.7 | -1.24 % | $ 2.61 B | ||
|
Aptorum Group Limited
APM
|
1.19 M | $ 0.84 | 7.59 % | $ 4.58 M | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Axsome Therapeutics
AXSM
|
-166 M | $ 166.38 | 1.52 % | $ 8.28 B | ||
|
AbCellera Biologics
ABCL
|
-199 M | $ 3.82 | 5.82 % | $ 1.14 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
Burford Capital Limited
BUR
|
242 M | $ 8.73 | 3.44 % | $ 1.37 B | ||
|
Capricor Therapeutics
CAPR
|
-23 M | $ 26.86 | -3.83 % | $ 719 M | ||
|
Codexis
CDXS
|
-53.6 M | $ 1.02 | 0.99 % | $ 74.9 M | ||
|
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
Cellectis S.A.
CLLS
|
-131 M | $ 3.8 | -2.06 % | $ 116 M | ||
|
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | ||
|
Acer Therapeutics
ACER
|
-24.5 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
-57.6 M | - | - | $ 2.17 B | ||
|
CNS Pharmaceuticals
CNSP
|
-14.9 M | $ 3.13 | -0.95 % | $ 1.2 M | ||
|
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | ||
|
Collegium Pharmaceutical
COLL
|
64.9 M | $ 41.6 | -0.17 % | $ 1.32 B | ||
|
Corcept Therapeutics Incorporated
CORT
|
45.9 M | $ 35.97 | 0.76 % | $ 3.74 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
258 M | $ 23.88 | 3.47 % | $ 2.92 B | ||
|
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
-44.4 M | $ 8.35 | -2.57 % | $ 36.1 M | ||
|
Curis
CRIS
|
-44.3 M | $ 1.08 | -5.26 % | $ 6.81 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
-513 M | $ 40.68 | -1.02 % | $ 3.83 B | ||
|
Corvus Pharmaceuticals
CRVS
|
-23.3 M | $ 17.89 | -2.03 % | $ 859 M | ||
|
Champions Oncology
CSBR
|
6.15 M | $ 6.07 | 2.71 % | $ 82.9 M | ||
|
Citius Pharmaceuticals
CTXR
|
-42 M | $ 0.72 | -2.3 % | $ 4.84 M | ||
|
CEL-SCI Corporation
CVM
|
-24.2 M | $ 3.83 | -10.09 % | $ 244 M | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | ||
|
Daré Bioscience
DARE
|
-23.4 M | $ 1.61 | -5.29 % | $ 13.7 M | ||
|
DBV Technologies S.A.
DBVT
|
-114 M | $ 23.25 | 10.77 % | $ 2.26 B | ||
|
AgeX Therapeutics
AGE
|
-9.76 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | ||
|
Precision BioSciences
DTIL
|
-36.9 M | $ 4.33 | 3.1 % | $ 16.6 M | ||
|
AIkido Pharma
AIKI
|
-11.4 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
-146 M | $ 3.34 | 0.3 % | $ 1.2 M | ||
|
Dyadic International
DYAI
|
-8.23 M | $ 0.77 | -1.68 % | $ 22.2 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M | ||
|
Editas Medicine
EDIT
|
-245 M | $ 2.15 | -2.27 % | $ 177 M | ||
|
Edesa Biotech
EDSA
|
-6.83 M | $ 2.28 | 3.64 % | $ 7.29 M | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
Agios Pharmaceuticals
AGIO
|
-467 M | $ 29.2 | -3.41 % | $ 1.69 B | ||
|
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | ||
|
Equillium
EQ
|
-14.4 M | $ 1.92 | 5.49 % | $ 66.7 M |